Circulating Biomarkers of Colorectal Cancer (CRC)—Their Utility in Diagnosis and Prognosis
Open Access
- 28 May 2021
- journal article
- review article
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 10 (11) , 2391
Abstract
The global burden of colorectal cancer (CRC) is expected to increase, with 2.2 million new cases and 1.1 million annual deaths by 2030. Therefore, the establishment of novel biomarkers useful in the early diagnosis of CRC is of utmost importance. A number of publications have documented the significance of the overexpression of several specific proteins, such as inflammatory mediators, in CRC progression. However, little is known about the potential utility of these proteins as circulating blood tumor biomarkers of CRC. Therefore, in the present review we report the results of our previous original studies as well as the findings of other authors who investigated whether inflammatory mediators might be used as novel biomarkers in the diagnosis and prognosis of CRC. Our study revealed that among all of the tested proteins, serum M-CSF, CXCL-8, IL-6 and TIMP-1 have the greatest value in the diagnosis and progression of CRC. Serum TIMP-1 is useful in differentiating between CRC and colorectal adenomas, whereas M-CSF and CRP are independent prognostic factors for the survival of patients with CRC. This review confirms the promising significance of these proteins as circulating biomarkers for CRC. However, due to their non-specific nature, further validation of their sensitivity and specificity is required.Keywords
Funding Information
- Medical University of Białystok, Poland (Medical University of Białystok, Poland)
This publication has 120 references indexed in Scilit:
- Interleukin-8 and its receptor CXCR2 in the tumour microenvironment promote colon cancer growth, progression and metastasisBritish Journal of Cancer, 2012
- MMP-2 and MMP-9 in normal mucosa are independently associated with outcome of colorectal cancer patientsBritish Journal of Cancer, 2012
- The diagnostic value of matrix metalloproteinase 9 (MMP-9) and tissue inhibitor of matrix metalloproteinases 1 (TIMP-1) determination in the sera of colorectal adenoma and cancer patientsInternational Journal of Colorectal Disease, 2010
- Chemokines and chemokine receptors: new insights into cancer-related inflammationTrends in Molecular Medicine, 2010
- Chemokines and Chemokine Receptors: Standing at the Crossroads of Immunobiology and NeurobiologyImmunity, 2009
- CXCL10 expression and prognostic significance in stage II and III colorectal cancerMolecular Biology Reports, 2009
- Active MMP‐2 effectively identifies the presence of colorectal cancerInternational Journal of Cancer, 2009
- Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseasesCell Research, 2008
- Role of chemokines in tumor growthCancer Letters, 2007
- Recent cancer survival in Europe: a 2000–02 period analysis of EUROCARE-4 dataThe Lancet Oncology, 2007